Naoto T Ueno, MD, PhD (@teamoncology) ranks #24 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: OPTIMA (UK), ASCENT03, ASCENT-04. CMS Open Payments lists $28,704 in 2025 general payments.
At a Glance
- 4 posts naming a trial in 2026
- 4 trials discussed by name
- Breast Cancer: US #24 · 3 physicians engaged
- CMS Open Payments lists $28,704 in 2025 general payments.
This Month
What Naoto T Ueno, MD, PhD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Naoto T Ueno, MD, PhD
Physicians who reposted Naoto T Ueno, MD, PhD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #24 | — | 3 | 4 | Full ranking |
What Colleagues Are Saying About Naoto T Ueno, MD, PhD
2026 posts by fellow physicians that mention @teamoncology, quoted word for word.
Thank you @teamoncology for navigating me for more than 10 years since I was a med student back in Japan! I finally became ready to start my faculty career from this summer thanks to his tremendous career mentorship. #AACR26 https://t.co/d5XJS27l3h
Congrats and thanks #YanningXu for presenting our collaborative @apoddc work on #regulatorydelays and #reimbursement at @myESMO #ESMO26! #ValerieHeong #BenTran @fredtingmd #DanielTan @teamoncology #VoonPeiJye #DaphneDay @ToshioShim1025 #TakafumiKoyama #MichelleWilson #ThalVo and many others.
Trials Naoto T Ueno, MD, PhD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| OPTIMA (UK) | 2 | #11 of 24 | May 30, 2026 |
| ASCENT03 | 1 | #17 of 19 | May 31, 2026 |
| ASCENT-04 | 1 | #24 of 24 | May 31, 2026 |
| lidERA | 1 | #22 of 23 | May 30, 2026 |
Naoto T Ueno, MD, PhD on OPTIMA (UK)
OPTIMA study is the most practice changing for breast cancer at #ASCO26. No chemotherapy for low ROS score, 50 gene Prosigna by @Veracyte, for much more advanced early breast cancer compared to OncotypeDx indication by @ExactSciences. https://t.co/doMgW9boAP
The issue with the OPTIMA study is that it doesn’t include a limited non-white population. Does this truly apply to all patient populations? #ASCO26
Naoto T Ueno, MD, PhD on ASCENT03
Both ASCENT-04 and ASCENT-03 efficacy is lbiomarker independent. Is this surprising? Not really. We have seen a similar pattern across the DESTINY-Breast studies, where no biomarker has been statistically meaningful enough to clearly define who benefits. This may be a
Naoto T Ueno, MD, PhD on ASCENT-04
Both ASCENT-04 and ASCENT-03 efficacy is lbiomarker independent. Is this surprising? Not really. We have seen a similar pattern across the DESTINY-Breast studies, where no biomarker has been statistically meaningful enough to clearly define who benefits. This may be a
Naoto T Ueno, MD, PhD on lidERA
LiDERA BC study showed that the giredestrant works for any menopause status. Also no difference in side effects profile. Safe and effective. This will be the next standard of care. How to balance with adjuvant CDK 4/6 inhibitor. https://t.co/mutGzibBCZ
Naoto T Ueno, MD, PhD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Congratulations to @waraonc23 Dr. Yu Fujiwara for receiving a grant from @AACR. He is a medical oncology fellow at @RoswellPark. It was a great opportunity to meet his wife at #AACR26. https://t.co/8SEG3UNlyG
Great to see all the superstar contributors to the advancement of cancer reseacer at the @AACRPres Presidental Dinner. @Rndubois @DrRoyHerbst @SenduraiMani https://t.co/WsitbTda3t
Dr Jason Lee presenting our new potent ADC for various cancer. The work of @UHCancerCenter preclinical core. Visit section 49 poster poster 10. https://t.co/UTl7xqHjg4 https://t.co/RIaToXo7Qx
The opening ceremony brings three new, interesting initiatives by @AACRPres: Opening of AACR Office in Singapore, New Asia-based AACR conference. And new Professional Excellence Program for early investigators. #AACR26 https://t.co/UMkPaDjVih
I’m thrilled to attend Dr. @AACRPres Lillian Siu’s speech tomorrow. There are many exciting new developments that will make cancer research more global, and I’m particularly impressed by the commitment to the next generation of cancer researchers. #AACR26 https://t.co/Z2SvDEC3gG
Industry Payments
CMS Open Payments · 2025 general payments
$28,704 across 20 payments